pages · PDF
Post-viral syndromes are an immune-reset failure — not a willpower problem. Research describes three persistent failures: ongoing immune activation without an active threat, mitochondrial NAD+ depletion from the viral immune response, and T-cell exhaustion that leaves immunity simultaneously overactivated and underperforming. Thymosin Alpha-1 — FDA-approved as adjunctive therapy for melanoma and hepatitis B and authorized in 35+ countries for hepatitis, immunodeficiency, and vaccine-adjuvant use — addresses the T-cell training failure at its source. The 3-phase ramp (Acute Recovery → Rebuilding → Maintenance) is paired with BPC-157 as the anti-inflammatory floor and NMN for NAD+ restoration. This is the strongest regulatory-credibility anchor in the entire Dosecraft compound library.
Unlock: Post-Viral Recovery — Immune Reconstitution Quick-Start
Enter your details to get instant access to this free guide.
No spam. We respect your privacy.
“These guides saved me weeks of research. The evidence ratings alone changed how I approach my protocols.”
-- Verified DoseCraft user
Why this matters
If you've been told post-viral fatigue, long-COVID, or post-infection cognitive symptoms are something you wait out — the literature describes a different option. The pattern is impossible to ignore post-2020: immune systems failing to reset after viral illness, producing months of fatigue, cognitive difficulty, inflammatory symptoms, and immune dysregulation. Research describes three persistent failures behind this picture — ongoing immune activation without an active threat, mitochondrial damage from the viral immune response, and T-cell exhaustion that leaves immunity simultaneously overactivated and underperforming. One compound — Thymosin Alpha-1 — holds FDA adjunctive-therapy approval for melanoma and hepatitis B, with regulatory authorization in 35+ countries as immune-reconstitution therapy. It is the most regulator-supported peptide in the entire Dosecraft compound library, and it addresses the T-cell training failure at its source. No bro-science. No name-drops.
What you'll learn
- Why post-viral syndromes are an immune-system reset failure, not a willpower problem
- How T-cell exhaustion produces the simultaneous over-activation + under-performance pattern the literature describes
- Why thymic involution amplifies the failure — and how TA-1 functions as a synthetic thymic output replacement
- Why Thymosin Alpha-1 has the strongest regulatory credibility in peptide medicine (FDA adjunctive approval + 35+ country authorization)
- The 3-phase TA-1 ramp — Acute Recovery, Rebuilding, Maintenance — and why it's not flat-dosed
- How BPC-157 provides the anti-inflammatory floor that lets immune reconstitution proceed
- Why NMN belongs in the stack (NAD+ depletion from viral immune response is research-described as a measurable mitochondrial failure)
- What NK cell + dendritic cell activation looks like as the immune system relearns proportional response
- How to track recovery objectively with CRP, d-dimer, ferritin, CBC differential, and the fatigue severity scale
The protocol at a glance
Dose
Thymosin Alpha-1 1.6 mg SubQ 2–3×/week (or daily in acute phase) · BPC-157 250–500 mcg SubQ 2×/day · NMN 500–1000 mg oral (sublingual preferred) daily AM
Frequency
TA-1 2–3×/week maintenance · BPC-157 twice daily · NMN once daily AM
Cycle
TA-1 phased: Acute Recovery 1.6 mg daily × 7–14 days → Rebuilding 1.0 mg daily × 4–8 weeks → Maintenance 1.0 mg daily ongoing (or 1.6 mg 2–3×/week) · BPC-157: 8–12 weeks on / 2–4 weeks off · NMN: ongoing daily, no cycling · Recheck inflammatory markers + CBC differential at 8 and 16 weeks
Timeline
BPC-157 anti-inflammatory effect: 2–4 weeks · TA-1 T-cell maturation signal: 2–6 weeks · Meaningful functional improvement: 8–12 weeks · Full immune-reconstitution endpoint: 16–24 weeks
Cautions
Active acute infection is a contraindication — TA-1 is for post-resolution reconstitution; treat the infection first. Active autoimmune flare requires physician coordination before TA-1 (the compound retrains immune education, which can transiently amplify activity before normalizing). Current immunosuppressive biologics (TNF-α inhibitors, JAK inhibitors, IL-6 inhibitors, etc.) require physician sign-off — the mechanisms intersect. Organ transplant recipients on anti-rejection medication should not run this protocol — anti-rejection drugs suppress the immune system intentionally; reconstitution is contraindicated. Pregnancy and breastfeeding: protocol washout required. This is a research synthesis, not medical advice — coordinate with a clinician familiar with post-viral immune protocols.
Is this for you?
- Adults with persistent symptoms ≥ 8 weeks after confirmed or suspected viral illness (long-COVID, post-mononucleosis, post-influenza, post-EBV reactivation)
- Users with documented inflammatory pattern post-infection (elevated CRP, ferritin, d-dimer, lymphocyte abnormalities on CBC)
- Anyone with the cognitive-fatigue + immune-dysregulation phenotype after viral infection
- Users who have ruled out active infection, thyroid dysfunction, iron deficiency, and sleep apnea as alternative explanations
- Adults willing to track recovery markers + symptom severity at baseline, week 8, and week 16
- Active infection of any kind — treat first; TA-1 is reconstitution therapy, not antimicrobial
- Current immunosuppressive biologic therapy without physician coordination
- Active autoimmune flare — stabilize first; coordinate with rheumatology / clinical immunology
- Organ transplant recipients on anti-rejection medication — contraindicated
- Pregnancy or breastfeeding
- Under 21 years of age
The mechanism — why it works
Post-viral syndromes are an immune-reset failure
Standard-of-care framing for long-COVID and post-viral fatigue is essentially 'wait it out' — supportive care, time, hope. The literature describes a more specific picture. Post-viral syndromes involve persistent immune activation that continues long after the infection clears, mitochondrial damage from the viral immune response that depletes the cellular energy floor, and T-cell exhaustion that leaves immune cells both chronically activated and functionally underperforming. These are not vague symptoms — they're measurable on inflammatory marker panels (elevated CRP, ferritin, d-dimer) and lymphocyte subset analyses. The immune system has lost the ability to recognize 'the infection is over' and recalibrate to baseline. The protocol addresses that reset failure directly.
The T-cell exhaustion model
When the immune system fights a prolonged viral infection, T-cells undergo what the literature describes as exhaustion — they continue to express activation markers but progressively lose effector function. PD-1 and other inhibitory receptors stay upregulated; cytokine output becomes dysregulated; the cells are stuck in a half-on, half-off state that produces inflammation without effective clearance. This is the cellular substrate of the paradox post-viral patients describe: 'I feel inflamed and exhausted at the same time, and my immune system seems to be both overreacting and not working.' Both observations are correct. The immune system is overactivated AND underperforming simultaneously — that's what exhaustion means at the cellular level. Reversing exhaustion requires retraining the immune-education process at the source.
Thymic involution amplifies the failure
The thymus is the immune system's training academy — the gland behind the sternum where T-cells learn friend-from-foe recognition before being released. After puberty, the thymus shrinks progressively at roughly 1–3% mass loss per year. By age 50, approximately 80% of functional thymic tissue is gone, replaced by fatty deposits. Naive T-cell output declines in parallel. The aging immune system increasingly relies on memory T-cells rather than newly-educated ones — which is exactly the wrong substrate for handling a novel viral challenge that requires fresh T-cell education. Post-viral failure happens earlier and harder in patients with significant thymic involution, because there's no naive T-cell production line to replace the exhausted population. This is what TA-1 directly addresses.
Thymosin Alpha-1 — the FDA-halo compound and synthetic thymic output replacement
TA-1 is a 28-amino-acid peptide naturally produced by the thymus that drives immature T-cells to functional competence. It does not boost the immune system. It does not suppress the immune system. It trains it — restoring the educational signal the shrinking thymus can no longer produce in adequate quantities. The regulatory credibility here is the strongest in the entire Dosecraft compound library: FDA adjunctive-therapy approval for melanoma and hepatitis B; full approval in 35+ countries for hepatitis, immunodeficiency, and use as a vaccine adjuvant; decades of clinical safety data in hospital protocols across multiple continents. Practitioners use TA-1 clinically for hepatitis B treatment, HIV immune reconstitution, and post-chemotherapy immune recovery — the same reconstitution problem the post-viral protocol addresses. This is research-described as functioning as a synthetic thymic output replacement: providing the molecular signals the involuted thymus can no longer supply at adequate concentration.
Why the FDA halo matters editorially and clinically
Most peptides in the practitioner toolkit operate in a research-and-clinical-use space without formal FDA approval — the regulatory framework hasn't caught up with the science. TA-1 is the exception. Its FDA adjunctive-therapy approval for melanoma and hepatitis B means the compound has been through the full Phase 1/2/3 clinical trial pipeline, the manufacturing controls audit, and the post-marketing safety surveillance program. Its approval in 35+ countries for hepatitis, immunodeficiency, and vaccine-adjuvant indications means multiple national regulatory bodies independently reviewed the data and reached the same conclusion. For patients evaluating peptide medicine, TA-1 is the strongest credibility anchor available: a compound that has cleared regulatory bars in dozens of countries for indications that share the underlying mechanism (immune training, T-cell education, restored proportional response) with the post-viral reconstitution use. Clinical practitioners report that this regulatory profile makes TA-1 the easiest peptide to integrate into existing physician relationships — the conversation starts from a foundation of formal regulatory authorization rather than research-only status.
The 3-phase TA-1 ramp — Acute Recovery, Rebuilding, Maintenance
TA-1 in post-viral reconstitution is not flat-dosed. The literature describes a 3-phase ramp that maps onto the underlying biology. Phase 1 — Acute Recovery: 1.6 mg SubQ daily × 7–14 days. The goal is rapid T-cell maturation, restoring CD4/CD8 ratios, and re-establishing the immune-education signal at high concentration. Phase 2 — Rebuilding: 1.0 mg SubQ daily × 4–8 weeks. Sustained immune education at a maintenance signal level; NK cell activation; dendritic cell maturation. Phase 3 — Maintenance: 1.0 mg SubQ daily ongoing (or 1.6 mg 2–3×/week for less acute reconstitution work). Preserve the immune competence the first two phases established; prevent reinfection vulnerability; maintain the proportional-response baseline. The ramp mirrors how a real thymus would handle a high-demand recovery period followed by return to maintenance signaling. Skipping the acute phase blunts the early reconstitution signal; skipping maintenance allows the exhaustion pattern to reassert.
BPC-157 — the anti-inflammatory floor
Reconstitution can't happen on top of an actively burning fire. The chronic inflammatory pattern post-viral patients carry — elevated IL-6, TNF-α, NF-κB activation — is exactly the environment that perpetuates T-cell exhaustion. BPC-157 provides the anti-inflammatory floor: research describes BPC-157 modulating NF-κB, upregulating IL-10 (the regulatory anti-inflammatory cytokine), and restoring tight-junction proteins (gut-barrier disruption is a frequent contributor to post-viral inflammatory load). The dose for this indication is 250–500 mcg SubQ twice daily — split dosing maintains a steadier serum concentration than once-daily injection, which matters when the goal is dampening a chronic inflammatory pattern rather than treating a localized injury. Research describes meaningful anti-inflammatory effect within 2–4 weeks — quicker than the TA-1 immune reconstitution signal, which is why BPC-157 effectively prepares the substrate that TA-1 then works on.
The mitochondrial dimension — NAD+ depletion and NMN
Viral infections drive massive NAD+ consumption. The PARP (poly-ADP-ribose polymerase) enzymes activated by viral DNA damage and the CD38 enzyme upregulated during immune responses both deplete cellular NAD+. The literature describes measurable post-viral NAD+ shortage — a mitochondrial energy crisis that explains why post-viral fatigue feels different from ordinary tiredness. Without sufficient NAD+, electron transport chain efficiency drops, ATP production stalls, and cells can't keep up with metabolic demand even at rest. NMN (nicotinamide mononucleotide) is a direct NAD+ precursor that restores the cofactor pool. The 500–1000 mg daily oral dose (sublingual administration preferred for bioavailability) is research-described as the practical floor for measurable NAD+ restoration. This is the mitochondrial-axis intervention that closes the third failure — without it, the immune reconstitution from TA-1 and the anti-inflammatory floor from BPC-157 are operating on cells that still can't generate adequate ATP for proper function.
NK cells, dendritic cells, and the proportional-response return
Two cell populations are particularly affected by post-viral exhaustion and particularly responsive to TA-1 reconstitution: natural killer (NK) cells and dendritic cells. NK cells are the immune system's first responders against infected or malignant cells — they recognize 'something is wrong here' faster than the adaptive arm and provide the initial containment. Dendritic cells are the antigen-presenting interface that educates new T-cells about what they should respond to. Both populations show measurable functional restoration with TA-1 across the published clinical literature, particularly in the Rebuilding phase. The subjective experience as these populations recover: patients describe a return of proportional immune response — minor exposures (a cold passing through the household, a small wound) provoke an appropriate quick response rather than either no response or a disproportionate inflammatory cascade. This is what 'the immune system is working again' looks like at the day-to-day level.
Monitoring dashboard — CRP, d-dimer, ferritin, CBC, fatigue severity scale
Post-viral recovery is measurable. The literature describes a tracking panel that produces objective signal alongside the subjective improvement: high-sensitivity CRP (target trending toward < 1.0 mg/L — chronic inflammation); d-dimer (target trending toward normal range — microthrombosis pattern associated with long-COVID); ferritin (target trending toward normal range — both an iron-storage marker and a sensitive acute-phase reactant); CBC with differential (lymphocyte subset analysis; absolute lymphocyte count trending toward normal; neutrophil:lymphocyte ratio toward 1.5–2). Pair these with the Fatigue Severity Scale (FSS) or PROMIS Fatigue short-form at baseline, week 8, and week 16 for the subjective endpoint. The combination — objective inflammatory + immune markers plus standardized fatigue assessment — gives an unambiguous answer to 'is this working' that neither markers nor symptoms alone can provide.
Foundational levers (not optional)
The research describes each as an independent driver. The protocol reduces their negative impact but doesn't eliminate it.
Sleep architecture is the substrate
Immune reconstitution concentrates during slow-wave sleep — the same window where GH pulses drive systemic repair. Under-slept patients on this protocol consistently respond more slowly. 7–8 hours with intact deep sleep is the floor. If sleep architecture is compromised, see the Sleep Architecture Reset guide before or alongside this protocol — the two are complementary, not competing.
Graded movement, not bed rest
Strict bed rest worsens post-viral deconditioning. Graded movement — short walks, low-intensity zone-2 work, gentle resistance training as tolerated — is research-described as the activity floor that supports mitochondrial recovery. Listen to post-exertional malaise signals; in the long-COVID phenotype specifically, pacing matters and pushing through is counterproductive. The goal is consistent low-grade activation, not heroic sessions.
Eliminate inflammatory amplifiers
Alcohol directly suppresses NK cell function and amplifies the chronic inflammatory pattern. Heavy sugar and seed-oil loads drive the same NF-κB activation TA-1 and BPC-157 are working to dampen. The protocol cannot fully compensate for daily alcohol or a heavily inflammatory dietary substrate. Even partial improvement here amplifies the protocol effect substantially.
Stress, HPA-axis, and vagal tone
Cortisol from chronic HPA-axis activation suppresses T-cell function directly. Vagal-tone work (slow nasal breathing, cold exposure, gargling, humming) downregulates the inflammatory branch of the autonomic nervous system. These aren't optional adjuncts — they're the upstream lever the protocol amplifies. The reconstitution signal works better in a parasympathetic-dominant baseline.
What you'll feel — week by week
Weeks 1–2
TA-1 acute-phase dosing (1.6 mg daily) drives the first reconstitution signal. Many users describe a subtle but consistent shift — small infections (minor cold symptoms, a paper cut) seem to provoke an appropriate response rather than the dysregulated pattern. BPC-157 anti-inflammatory effect begins. Energy is typically still flat in this window — the substrate is being prepared, not yet restored.
Weeks 3–6
Transition to TA-1 Rebuilding phase (1.0 mg daily). NK cell + dendritic cell activation begins. BPC-157 anti-inflammatory effect consolidates — patients with elevated baseline CRP often see measurable drops here. NMN's NAD+ restoration starts producing the subjective energy floor improvement — not a stimulant effect, more a 'reduced resting deficit' shift. Cognitive symptoms (post-viral brain fog, word-finding difficulty) often start to ease in this window.
Weeks 8–12
First objective bloodwork recheck. hs-CRP trending down. d-dimer trending toward normal. Ferritin normalizing. CBC differential showing improved lymphocyte populations. Subjective fatigue scale (FSS / PROMIS) shows measurable improvement. The literature describes this window as where meaningful functional recovery becomes clearly visible — patients describe being able to handle previously-exhausting activities (a half-day of work, an hour of light exercise, a social evening) without the post-exertional crash.
Weeks 16–24
Full immune-reconstitution endpoint. Compare inflammatory markers, CBC differential, and fatigue severity to baseline. Research describes meaningful functional recovery in a substantial majority of patients on the full combined protocol at this window. Decide: continue TA-1 maintenance dosing (1.0 mg daily or 1.6 mg 2–3×/week) for ongoing immune competence, or taper to intermittent dosing if reconstitution is stable. BPC-157 typically tapers here; NMN continues ongoing as part of broader longevity maintenance.
What could go wrong
Common (no action)
- Mild fatigue or transient symptom shift in TA-1 acute-phase week 1 — immune-modulation adaptation; resolves
- Mild GI symptoms with NMN at higher doses (1000 mg) — split AM/PM or reduce to 500 mg if persistent
- Mild injection-site reactions with TA-1 or BPC-157 — rotate locations
- Vivid dreams in week 1 — common BPC-157 systemic effect; benign
Watch + adjust
- Pre-existing autoimmune symptoms transiently amplifying in weeks 1–3 — TA-1 retrains immune education, which can briefly increase activity before normalizing; coordinate with rheumatology if significant
- Fatigue worsening rather than improving after week 6 — reassess for alternative drivers (thyroid, iron, sleep apnea, undiagnosed mitochondrial disease)
- Lymphadenopathy or unexplained fever — pause protocol, seek clinical evaluation (rule out unmasking of latent infection)
Stop + seek care
- Active infection emerging during the protocol — stop TA-1, treat the infection first, resume reconstitution after resolution
- Allergic reaction at any peptide injection site — emergency care
- Signs of autoimmune flare (joint swelling, characteristic rash, organ-specific symptoms) — stop and coordinate with clinical immunology
- New cancer diagnosis during the protocol — coordinate with oncology before continuing; TA-1 is FDA-approved as adjunctive therapy in melanoma and used clinically in multiple cancer protocols, but the decision belongs with the treating team
Bloodwork — what to track
Primary outcome markers: hs-CRP (target trending toward < 1.0 mg/L — chronic inflammation), d-dimer (target trending toward normal — microthrombosis pattern), ferritin (target trending toward normal — acute-phase reactant + iron storage), CBC with differential including lymphocyte subsets where available (target normalizing absolute lymphocyte count + neutrophil:lymphocyte ratio toward 1.5–2). Subjective endpoint: Fatigue Severity Scale (FSS) or PROMIS Fatigue short-form at baseline, week 8, and week 16. Supporting panel: comprehensive metabolic panel, TSH + free T4 (rule out post-viral thyroid involvement), iron panel (rule out post-viral iron metabolism disruption), NK cell activity testing where available. Full bloodwork target table + post-viral tracker worksheet in the paid pack.
Frequently asked
Is Thymosin Alpha-1 actually FDA-approved? What does 'adjunctive' mean?
Yes. TA-1 holds FDA approval as adjunctive therapy for melanoma and hepatitis B — meaning the FDA has reviewed the full clinical trial data and authorized its use alongside standard treatments for those indications. 'Adjunctive' means it's used WITH another therapy, not as a sole treatment. Beyond the US, TA-1 is fully approved in 35+ countries for hepatitis, immunodeficiency, and use as a vaccine adjuvant. This is the most extensive regulatory authorization in the entire Dosecraft compound library — most peptides operate in research-and-clinical-use space without formal approval. TA-1 cleared the Phase 1/2/3 trial pipeline, the manufacturing controls audit, and multi-country regulatory review. For post-viral reconstitution, the use is off-label in the US — but the underlying mechanism (immune training, T-cell education) is the same mechanism the approved indications rely on, and the safety profile is established across decades of clinical use.
Why three phases of TA-1 instead of one steady dose?
The 3-phase ramp — Acute Recovery (1.6 mg daily × 7–14 days), Rebuilding (1.0 mg daily × 4–8 weeks), Maintenance (1.0 mg daily ongoing or 1.6 mg 2–3×/week) — mirrors how a healthy thymus would handle a high-demand recovery period followed by return to maintenance signaling. The acute phase floods the system with reconstitution signal during the highest-need window; the rebuilding phase sustains immune education through NK and dendritic cell activation; maintenance preserves the competence the first two phases established. Skipping acute blunts the early reconstitution; skipping maintenance allows the exhaustion pattern to reassert over 3–6 months. This is research-described as the most clinically validated TA-1 reconstitution structure.
Do I really need all three compounds, or can I run TA-1 alone?
TA-1 monotherapy is conservative and has the cleanest regulatory profile — for patients who want the most established intervention, it's a reasonable starting point. The combined protocol addresses additional failure modes TA-1 alone doesn't reach: BPC-157 dampens the chronic inflammatory pattern that perpetuates exhaustion (otherwise reconstitution is happening on top of an actively burning fire); NMN restores the NAD+ pool depleted by the viral immune response (otherwise mitochondrial energy stays limited even as immunity recovers). Clinical practitioners report the combination producing faster and more complete recovery than TA-1 alone — particularly for patients with measurable baseline inflammation or significant fatigue burden.
I'm still having occasional COVID-like symptoms 6 months out. Is this protocol right for me?
First confirm there's no active reinfection — TA-1 is for post-resolution reconstitution, not active infection management. If acute infection is ruled out and the picture is persistent post-viral inflammation + fatigue + immune dysregulation, this is exactly the indication the protocol targets. The 16–24 week timeline is the realistic window for meaningful improvement; recovery is not measured in days. Pair the protocol with the lifestyle levers (graded movement, sleep, inflammatory dietary substrate, vagal-tone work) — these are not optional adjuncts.
Can I run this protocol if I have autoimmune disease in my history?
Coordinate with your rheumatologist or clinical immunologist first. TA-1's mechanism is immune education — it retrains the proportional-response system rather than blanket-stimulating or suppressing. In autoimmune contexts, the literature describes TA-1 actually helping normalize TH1/TH2 balance over time (which is part of why it shows benefit in conditions like Hashimoto's). However, transient amplification of pre-existing autoimmune activity is possible in early weeks as the immune education shifts. Active autoimmune flare is a contraindication — stabilize first. Stable autoimmune disease in remission with no current immunosuppressive biologic is the gray zone where physician-coordinated protocols make sense.
Post-Viral Recovery — what does recovery actually mean here?
Recovery means: inflammatory markers (hs-CRP, d-dimer, ferritin) trending toward or within normal range, CBC differential normalizing, Fatigue Severity Scale dropping into the normal-functioning range, and — most importantly — return to pre-illness functional capacity without post-exertional crashes. Research describes this outcome as achievable for a substantial majority of post-viral patients on the full combined protocol at 16–24 weeks. It's not guaranteed. Some patients with significant long-COVID burden require a second cycle or extended maintenance. But the framing — that post-viral syndromes are an immune-reset failure that can be addressed at the source rather than waited out — is categorically different from the standard 'support and hope' model, and TA-1's FDA-halo regulatory profile gives the conversation a credibility anchor most peptide protocols can't match.
Cited research
Verified Vendors
Where to get these compounds
Thymosin Alpha-1 is the regulatory-halo compound in this protocol — FDA-approved as adjunctive therapy for melanoma and hepatitis B; authorized in 35+ countries. Vial quality matters more here than almost any other indication because the dosing window is narrow and the reconstitution signal depends on intact peptide. Peptide Partners carries TA-1 in their core practitioner-tier catalog with HPLC + mass-spec verification and free replacement on failed third-party tests. BPC-157 is research-grade injectable; NMN is a supplement (sublingual form preferred). Source TA-1 and BPC-157 from the verified vendor below; NMN from any reputable supplement vendor. Reconstitution worksheet and 16-week tracking spreadsheet included in the bloodwork pack.
Peptide Partners
Practitioner-tier research peptides
HPLC + Mass-Spec verified · Free replacement on failed third-party tests
MyOasis Labs
Widest catalog — injectables, oral caps, blends
Third-party lab tested · Every batch
Hydro Research Peptides
Research-grade peptides — 20% off your order
Research peptides · newest addition to the verified roster
Affiliate disclosure: DoseCraft earns a small commission on orders made through these vendor links — at no extra cost to you. We only partner with vendors that pass our internal vendor-rubric audit.
Ready for the full experience?
DoseCraft gives you AI-powered protocol building, 90+ compound library, dose tracking, and evidence-rated stacks from leading practitioners.
Get Started — Try DoseCraft NowNot medical advice — educational only. These guides are for informational and research purposes only. Always consult a licensed healthcare professional before starting any peptide protocol.